New-onset of vitiligo in a child following COVID-19 vaccination

Bukhari, Abrar

doi:10.1016/j.jdcr.2022.02.021

Cited by 12 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 6 , 7 All of them were adults except for one 13‐year‐old girl. 5 All patients reported that their lesions appeared approximately 1–2 weeks after the first dose of the vaccine, with the exception of one patient, who developed only very faint hypopigmented macules after the first dose, which progressed to overt vitiligo after the second dose, as was the case in our patient. 6 In another patient, no deterioration was reported after the second dose of the vaccine.…”

Section: Figuresupporting

confidence: 65%

See 1 more Smart Citation

New‐onset vitiligo after COVID‐19 mRNA vaccination: A causal association?

Nicolaidou

Vavouli

Koumprentziotis

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Dear Editor, Given the widespread vaccination of the population with the novel mRNA vaccines against COVID-19, it is of utmost importance to identify any possible adverse effects they may have. In clinical trials with the BNT162b2 COVID-19 mRNA vaccine (Pfizer-ΒioNTech), adverse effects included mostly injection-site reactions, fatigue and headache. 1 Herein, we report a case of vitiligo following vaccination with the BNT162b2 COVID-19 mRNA vaccine (Pfizer/ BioNTech).A 69-year-old male presented with white macules on his face, abdomen, back, and upper and lower limbs that covered approximately 20% of his total body surface area (Figure 1). The lesions had appeared several months before his presentation, 3 days after his second dose of the BNT162b2 COVID-19 mRNA vaccine (Pfizer/BioNTech). The patient reported that the lesions appeared initially on the dorsal area of his hands, progressed to the rest of his body the following month and since then they had remained stable. There was no progression

show abstract

Section: Figuresupporting

confidence: 65%

“…To our knowledge, six other mRNA vaccine related vitiligo cases have been reported so far with four of them being related to the BNT162b2 COVID‐19 mRNA vaccine (Pfizer/BioNTech) 2 , 3 , 4 , 5 and two of them to the Moderna (mRNA‐1273) COVID‐19 vaccine. 6 , 7 All of them were adults except for one 13‐year‐old girl.…”

Section: Figurementioning

confidence: 99%

New‐onset vitiligo after COVID‐19 mRNA vaccination: A causal association?

Nicolaidou

Vavouli

Koumprentziotis

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…In fact, the patient had received the second dose of the AstraZeneca vaccine just a few weeks before the depigmented spots appeared. After reviewing the literature (Table 1 ), we found that some cases of vitiligo related to SARS‐CoV‐2 vaccination had been reported, 6 , 7 , 8 , 9 , 10 , 11 , 12 while no cases of eruptive halo nevi after COVID‐19 vaccination had been described so far. Vitiligo and halo nevi are closely connected to each other and share an immune‐mediated etiopathogenesis.…”

mentioning

confidence: 99%

Eruptive halo nevi: A new COVID‐19 vaccine‐related cutaneous adverse event or a paraneoplastic phenomenon?

Giorgi

Colombo

Gemignani

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“… BNT162b2:31 mRNA-1273: 5 AZD1222: 19 Ad26.COV2: 0 Chilblains-like/pernio 12 Russo et al 188 (3), Paparella et al 189 (1), Davido et al 190 (1), Lopez et al 191 (1), Pileri et al 192 (1), Piccolo et al 193 (1), Pérez-López et al 194 (1), Cameli et al 195 (1), Kha et al 196 (1), Lesort et al 197 (1). BNT162b2:9 mRNA-1273: 2 AZD1222: 1 Ad26.COV2: 0 Vitiligo 11 Kaminetsky et al 198 (1), Militello et al 199 (1), Singh et al 200 (1), Nicolaidou et al 201 (1), Flores-Terry et al 202 (1), Bukhari et al 203 (1), Uğurer et al 204 (1), Ciccarese et al 205 (1), López Riquelme et al 206 (1), Okan et al 207 (1), Caroppo et al 208 (1). BNT162b2: 7 mRNA-1273: 3 AZD1222: 1 Ad26.COV2: 0 Abbreviations : BNT162b2, Pfizer mRNABNT162b2; mRNA-1273, Moderna mRNA-1273; AZD1222, AstraZeneca-Oxford AZD1222; Ad26.COV2, Johnson & Johnson Ad26.COV2.S.…”

Section: Methodsmentioning

confidence: 99%

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

show abstract

New-onset of vitiligo in a child following COVID-19 vaccination

Cited by 12 publications

References 8 publications

New‐onset vitiligo after COVID‐19 mRNA vaccination: A causal association?

New‐onset vitiligo after COVID‐19 mRNA vaccination: A causal association?

Eruptive halo nevi: A new COVID‐19 vaccine‐related cutaneous adverse event or a paraneoplastic phenomenon?

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Contact Info

Product

Resources

About